Economic burden of cancer care in Lebanon’s privately insured population: a seven-year retrospective cohort analysis (2018–2024) - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Financial Impact of Cancer Treatment on Privately Insured Individuals in Lebanon: A Seven-Year Retrospective Cohort Study (2018–2024)

  • By

  • Shadi Saleh

  • Paul Makhoul

  • Rawad Chamandi

  • Zahi Abdul-Sater

  • August 25, 2026

Share

  • 1

    A retrospective cohort study analyzed cancer treatment costs for privately insured individuals in Lebanon from 2018 to 2024.

  • 2

    The study included 16,617 unique cancer patients, generating 157,550 claims and a total expenditure of USD 239.9 million.

  • 3

    Breast cancer was the most common diagnosis, accounting for 19.7% of cases, with surgery being the most utilized treatment modality.

  • 4

    Annual cancer treatment spending increased from USD 35.7 million in 2018 to USD 48.9 million in 2024, despite a temporary decrease in 2022.

  • 5

    The high-cost cohort, comprising 1.7% of patients, generated 23.0% of total spending, with lung cancer being the most prevalent in this group.

Original Source(s)

Related Content